These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 37005530)

  • 1. First Approval of Adagrasib for the Treatment of Non-Small Cell Lung Cancer Harboring a
    De SK
    Curr Med Chem; 2024; 31(3):266-272. PubMed ID: 37005530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adagrasib: First Approval.
    Dhillon S
    Drugs; 2023 Feb; 83(3):275-285. PubMed ID: 36763320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced
    Ou SI; Jänne PA; Leal TA; Rybkin II; Sabari JK; Barve MA; Bazhenova L; Johnson ML; Velastegui KL; Cilliers C; Christensen JG; Yan X; Chao RC; Papadopoulos KP
    J Clin Oncol; 2022 Aug; 40(23):2530-2538. PubMed ID: 35167329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adagrasib Treatment After Sotorasib-Related Hepatotoxicity in Patients With
    Luo J; Florez N; Donnelly A; Lou Y; Lu K; Ma PC; Spira AI; Ryan D; Husain H
    JCO Precis Oncol; 2024 Apr; 8():e2300644. PubMed ID: 38579193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adagrasib: a novel inhibitor for
    Guo MZ; Marrone KA; Spira A; Rosner S
    Future Oncol; 2023 May; 19(15):1037-1051. PubMed ID: 37133216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro Experiments.
    Koga T; Suda K; Fujino T; Ohara S; Hamada A; Nishino M; Chiba M; Shimoji M; Takemoto T; Arita T; Gmachl M; Hofmann MH; Soh J; Mitsudomi T
    J Thorac Oncol; 2021 Aug; 16(8):1321-1332. PubMed ID: 33971321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sotorasib as First-Line Treatment for Advanced KRAS G12C-Mutated Non-Small Cell Lung Carcinoma: A Case Report.
    Iska S; Alley EW
    Case Rep Oncol; 2023; 16(1):177-181. PubMed ID: 37008835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adagrasib in Advanced Solid Tumors Harboring a
    Bekaii-Saab TS; Yaeger R; Spira AI; Pelster MS; Sabari JK; Hafez N; Barve M; Velastegui K; Yan X; Shetty A; Der-Torossian H; Pant S
    J Clin Oncol; 2023 Sep; 41(25):4097-4106. PubMed ID: 37099736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. KRAS G12C in advanced NSCLC: Prevalence, co-mutations, and testing.
    Lim TKH; Skoulidis F; Kerr KM; Ahn MJ; Kapp JR; Soares FA; Yatabe Y
    Lung Cancer; 2023 Oct; 184():107293. PubMed ID: 37683526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CodeBreak 200: Sotorasib Has Not Broken the KRAS
    Zhang SS; Lee A; Nagasaka M
    Lung Cancer (Auckl); 2023; 14():27-30. PubMed ID: 37101895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CodeBreaK 200: Sotorasib (AMG510) Has Broken the
    Brazel D; Kim J; Ou SI
    Lung Cancer (Auckl); 2023; 14():31-39. PubMed ID: 37101896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sotorasib: a treatment for non-small cell lung cancer with the KRAS G12C mutation.
    Zheng X; Luo J; Liu W; Ashby CR; Chen ZS; Lin L
    Drugs Today (Barc); 2022 Apr; 58(4):175-185. PubMed ID: 35412531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted therapies for KRAS-mutant non-small cell lung cancer: from preclinical studies to clinical development-a narrative review.
    Santarpia M; Ciappina G; Spagnolo CC; Squeri A; Passalacqua MI; Aguilar A; Gonzalez-Cao M; Giovannetti E; Silvestris N; Rosell R
    Transl Lung Cancer Res; 2023 Feb; 12(2):346-368. PubMed ID: 36895930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A real-world pharmacovigilance study of KRAS G12C mutation inhibitors based on the food and drug administration adverse event reporting system.
    Wu L; Xu M; Li X; Aierken D; Yu J; Qin T
    Front Pharmacol; 2024; 15():1418469. PubMed ID: 39263575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adagrasib in Non-Small-Cell Lung Cancer Harboring a
    Jänne PA; Riely GJ; Gadgeel SM; Heist RS; Ou SI; Pacheco JM; Johnson ML; Sabari JK; Leventakos K; Yau E; Bazhenova L; Negrao MV; Pennell NA; Zhang J; Anderes K; Der-Torossian H; Kheoh T; Velastegui K; Yan X; Christensen JG; Chao RC; Spira AI
    N Engl J Med; 2022 Jul; 387(2):120-131. PubMed ID: 35658005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pharmacological characteristics and clinical study results of the first RAS inhibitor sotorasib (LUMAKRAS
    Hoshiyama H
    Nihon Yakurigaku Zasshi; 2023; 158(5):391-398. PubMed ID: 37673617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective KRAS G12C inhibitors in non-small cell lung cancer: chemistry, concurrent pathway alterations, and clinical outcomes.
    Palma G; Khurshid F; Lu K; Woodward B; Husain H
    NPJ Precis Oncol; 2021 Nov; 5(1):98. PubMed ID: 34845311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of ULK1/2 and KRAS
    Ghazi PC; O'Toole KT; Srinivas Boggaram S; Scherzer MT; Silvis MR; Zhang Y; Bogdan M; Smith BD; Lozano G; Flynn DL; Snyder EL; Kinsey CG; McMahon M
    bioRxiv; 2024 Jun; ():. PubMed ID: 38370808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent progress in targeting KRAS mutant cancers with covalent G12C-specific inhibitors.
    Rathod LS; Dabhade PS; Mokale SN
    Drug Discov Today; 2023 May; 28(5):103557. PubMed ID: 36934967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Editorial: Recent Approval of Sotorasib as the First Targeted Therapy for KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer (NSCLC).
    Parums DV
    Med Sci Monit; 2022 Nov; 28():e938746. PubMed ID: 36317327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.